High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil - PubMed (original) (raw)
Affiliations
- PMID: 9796967
High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil
R Metzger et al. Clin Cancer Res. 1998 Oct.
Abstract
The gene expression levels of the nucleoside cleavage enzyme/angiogenic factor thymidine phosphorylase (TP), also known as platelet-derived endothelial cell growth factor, were measured by quantitative reverse transcription-PCR in 38 pretreatment biopsies of colorectal tumors from patients who were subsequently treated with 5-fluorouracil (5-FUra) and leucovorin (LV). The range of TP gene expression (relative mRNA levels) in those tumors nonresponsive to 5-FUra was much broader than that of the responding tumors. In contrast to in vitro studies that had shown that an increased intracellular level of TP potentiates the activity of 5-FUra by converting it to the more cytotoxic nucleoside form 5-fluoro-2'deoxyuridine, tumors with the highest basal TP expressions were nonresponders to 5-FUra/LV therapy. The mean TP mRNA level in the nonresponding tumors was 2.6-fold higher than that of the responding patients. We had shown previously that high expression of thymidylate synthase (TS), the target enzyme of 5-FUra, was also a predictor of nonresponse to 5-FUra (L. Leichman et al, J. Clin. Oncol., 15: 3223-3229, 1997). TP and TS expressions were found to be independent variables in these tumors, so that low expression levels of both TS and TP in tumors predicted a very high response rate (11 of 14) to 5-FUra/LV as well as a significantly longer survival, whereas none (0 of 24) of the patients with high expression of either TP or TS were responders.
Similar articles
- Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.
Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV. Salonga D, et al. Clin Cancer Res. 2000 Apr;6(4):1322-7. Clin Cancer Res. 2000. PMID: 10778957 Clinical Trial. - Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M, Quirino M, Schinzari G, Zannoni G, Corsi DC, Vecchio FM, Cassano A, La Torre G, Barone C. Ciaparrone M, et al. Oncology. 2006;70(5):366-77. doi: 10.1159/000098110. Epub 2006 Dec 15. Oncology. 2006. PMID: 17179731 - Thymidine phosphorylase: the unforeseen driver in colorectal cancer treatment?
Tampellini M, Bironzo P, Di Maio M, Scagliotti GV. Tampellini M, et al. Future Oncol. 2018 May;14(12):1223-1231. doi: 10.2217/fon-2017-0627. Epub 2018 Apr 27. Future Oncol. 2018. PMID: 29701074 Review. - Thymidine phosphorylase and fluoropyrimidines efficacy: a Jekyll and Hyde story.
Ciccolini J, Evrard A, Cuq P. Ciccolini J, et al. Curr Med Chem Anticancer Agents. 2004 Mar;4(2):71-81. doi: 10.2174/1568011043482089. Curr Med Chem Anticancer Agents. 2004. PMID: 15032715 Review.
Cited by
- Limits to thymidylate synthase and TP53 genes as predictive determinants for fluoropyrimidine sensitivity and further evidence for RNA-based toxicity as a major influence.
Brody JR, Hucl T, Costantino CL, Eshleman JR, Gallmeier E, Zhu H, van der Heijden MS, Winter JM, Wikiewicz AK, Yeo CJ, Kern SE. Brody JR, et al. Cancer Res. 2009 Feb 1;69(3):984-91. doi: 10.1158/0008-5472.CAN-08-3610. Epub 2009 Jan 20. Cancer Res. 2009. PMID: 19155291 Free PMC article. - Thymidine phosphorylase mRNA expression may be a predictor of response to post-operative adjuvant chemotherapy with S-1 in patients with stage III colorectal cancer.
Ogawa M, Watanabe M, Mitsuyama Y, Anan T, Ohkuma M, Kobayashi T, Eto K, Yanaga K. Ogawa M, et al. Oncol Lett. 2014 Dec;8(6):2463-2468. doi: 10.3892/ol.2014.2574. Epub 2014 Sep 29. Oncol Lett. 2014. PMID: 25364408 Free PMC article. - Protein and mRNA expression of folic acid-associated enzymes as biomarkers for the cytotoxicity of the thymidylate synthase-targeted drugs, pemetrexed and S-1, in non-small cell lung cancer.
Kimura M, Imamura F, Inoue T, Nishino K, Uchida J, Kumagai T, Okami J, Higasiyama M, Kamoshida S. Kimura M, et al. Mol Clin Oncol. 2017 Jul;7(1):15-23. doi: 10.3892/mco.2017.1262. Epub 2017 May 16. Mol Clin Oncol. 2017. PMID: 28685068 Free PMC article. - Molecular markers in colorectal cancer: genetic bases for a customised treatment.
Casado E, De Castro J, Belda-Iniesta C, Cejas P, Feliu J, Sereno M, González-Barón M. Casado E, et al. Clin Transl Oncol. 2007 Sep;9(9):549-54. doi: 10.1007/s12094-007-0102-8. Clin Transl Oncol. 2007. PMID: 17921101 Review. - Thymidine phosphorylase affects clinical outcome following surgery and mRNA expression levels of four key enzymes for 5-fluorouracil metabolism in patients with stage I and II non-small cell lung cancer.
Himuro N, Niiya Y, Minakata T, Oshima Y, Kataoka D, Yamamoto S, Suzuki T, Kadokura M. Himuro N, et al. Mol Clin Oncol. 2018 Dec;9(6):640-646. doi: 10.3892/mco.2018.1726. Epub 2018 Sep 25. Mol Clin Oncol. 2018. PMID: 30546894 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical